Literature DB >> 4525537

Systemic lysostaphin in man--apparent antimicrobial activity in a neutropenic patient.

F R Stark, C Thornsvard, E P Flannery, M S Artenstein.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1974        PMID： 4525537     DOI： 10.1056/NEJM197408012910507

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  19 in total

1.  Depletion of T cell epitopes in lysostaphin mitigates anti-drug antibody response and enhances antibacterial efficacy in vivo.

Authors:  Hongliang Zhao; Deeptak Verma; Wen Li; Yoonjoo Choi; Christian Ndong; Steven N Fiering; Chris Bailey-Kellogg; Karl E Griswold
Journal:  Chem Biol       Date:  2015-05-21

2.  Production of Lysostaphin by Nonproprietary Method Utilizing a Promoter from Toxin-Antitoxin System.

Authors:  Anna Mądry; Agnieszka Jendroszek; Grzegorz Dubin; Benedykt Wladyka
Journal:  Mol Biotechnol       Date:  2019-10       Impact factor: 2.695

3.  Electrostatic-Mediated Affinity Tuning of Lysostaphin Accelerates Bacterial Lysis Kinetics and Enhances In Vivo Efficacy.

Authors:  Hongliang Zhao; Susan Eszterhas; Jacob Furlon; Hao Cheng; Karl E Griswold
Journal:  Antimicrob Agents Chemother       Date:  2021-03-18       Impact factor: 5.191

4.  Inhibition of Staphylococcus aureus by lysostaphin-expressing Lactobacillus plantarum WCFS1 in a modified genital tract secretion medium.

Authors:  Huanli Liu; Yuan Gao; Li-Rong Yu; Richard C Jones; Christopher A Elkins; Mark E Hart
Journal:  Appl Environ Microbiol       Date:  2011-10-07       Impact factor: 4.792

5.  Mechanism and suppression of lysostaphin resistance in oxacillin-resistant Staphylococcus aureus.

Authors:  M W Climo; K Ehlert; G L Archer
Journal:  Antimicrob Agents Chemother       Date:  2001-05       Impact factor: 5.191

6.  Gene and protein sequence optimization for high-level production of fully active and aglycosylated lysostaphin in Pichia pastoris.

Authors:  Hongliang Zhao; Kristina Blazanovic; Yoonjoo Choi; Chris Bailey-Kellogg; Karl E Griswold
Journal:  Appl Environ Microbiol       Date:  2014-02-21       Impact factor: 4.792

7.  Lysostaphin treatment of experimental aortic valve endocarditis caused by a Staphylococcus aureus isolate with reduced susceptibility to vancomycin.

Authors:  R L Patron; M W Climo; B P Goldstein; G L Archer
Journal:  Antimicrob Agents Chemother       Date:  1999-07       Impact factor: 5.191

8.  Lysostaphin treatment of experimental methicillin-resistant Staphylococcus aureus aortic valve endocarditis.

Authors:  M W Climo; R L Patron; B P Goldstein; G L Archer
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

9.  Organ injury and cytokine release caused by peptidoglycan are dependent on the structural integrity of the glycan chain.

Authors:  Anders E Myhre; Jon Fredrik Stuestøl; Maria K Dahle; Gunhild Øverland; Christoph Thiemermann; Simon J Foster; Per Lilleaasen; Ansgar O Aasen; Jacob E Wang
Journal:  Infect Immun       Date:  2004-03       Impact factor: 3.441

10.  Bioluminescence and 19F magnetic resonance imaging visualize the efficacy of lysostaphin alone and in combination with oxacillin against Staphylococcus aureus in murine thigh and catheter-associated infection models.

Authors:  Tobias Hertlein; Volker Sturm; Udo Lorenz; K Sumathy; Peter Jakob; Knut Ohlsen
Journal:  Antimicrob Agents Chemother       Date:  2013-12-23       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.